Celerion's Commitment to Climate Action through SBTi
Celerion, a prominent name in the field of early clinical research, has recently made a significant pledge to the Science Based Targets Initiative (SBTi). This commitment highlights the company’s dedication to sustainable practices and climate action as they prepare to set near-term and net-zero emission reduction targets across their operations.
Aligning Strategies for a Sustainable Future
Celerion's alignment with the SBTi underscores the urgency of addressing climate change. In an inspiring statement, CEO Susan Thornton expressed enthusiasm about their journey towards sustainability and the opportunity to collaborate with clients for a better future. This partnership reflects a proactive approach towards developing innovative solutions that can contribute to a global vision of sustainability.
The Role of the SBTi
The SBTi is a powerful coalition that includes influential organizations such as the CDP, the United Nations Global Compact, and the World Resources Institute. Their mission is pivotal: to guide companies worldwide in adopting ambitious emissions reduction targets. By maintaining a goal of limiting the global temperature increase to 1.5°C and achieving net-zero by 2050, the SBTi provides a structured path for organizations to follow.
Celerion's Contributions to Global Efforts
Celerion’s commitment to the SBTi is just one component of a broader vision focusing on sustainable development and environmental stewardship. With years of expertise in clinical research, Celerion is not only dedicated to encouraging advancements in drug development but also to actively participating in the collective battle against climate change. Their pledges signal an essential shift towards integrating sustainability into their operational ethos.
Fostering Collaboration for Innovation
By joining the ranks of leading pharmaceutical and biotechnology firms making strides to reduce greenhouse gas emissions, Celerion asserts its leadership in responsible business practices. The company is dedicated to instigating partnerships with various stakeholders to accelerate innovations aimed at achieving sustainability goals. This collaborative spirit is essential as the global community seeks shared solutions to pressing environmental issues.
About Celerion
Celerion stands as a leader in the realm of early clinical research, distinguished for its expert-driven services that empower pharmaceuticals and biotech companies to make informed decisions throughout drug development. With a rich history spanning over 50 years, Celerion excels in conducting Phase 1 studies, which include first-in-human trials, assessing drug-drug interactions, and evaluating pharmacokinetics among diverse patient populations. The company further enhances its offerings with comprehensive data management, biostatistics, clinical monitoring, and bioanalytical services. To learn more, interested parties are encouraged to visit Celerion's official website.
Frequently Asked Questions
What is Celerion's recent commitment?
Celerion has committed to the Science Based Targets Initiative (SBTi), focusing on setting emission reduction targets.
Why is Celerion's commitment to the SBTi important?
This commitment is crucial as it aligns Celerion with global efforts to combat climate change and reduce carbon emissions.
What are the goals of the SBTi?
The SBTi aims to help organizations set science-based goals to limit global warming to 1.5°C and achieve net-zero emissions by 2050.
Who leads the SBTi?
The SBTi is led by prominent organizations, including the CDP, the United Nations Global Compact, and the World Resources Institute.
How does Celerion plan to achieve its sustainability goals?
Celerion plans to align its operational strategies with SBTi guidelines, and collaborate with stakeholders to foster innovations for sustainability.
